Unlock instant, AI-driven research and patent intelligence for your innovation.

Quinuclidines-substituted-multi-cycli-heteroaryls for treatment of disease

A technology of compounds and substituents, applied in the field of quinuclidine-substituted polycyclic heteroaryl compounds for the treatment of diseases, capable of solving problems such as calcium ion blockade

Inactive Publication Date: 2004-07-07
PHARMACIA & UPJOHN CO
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In fact, Eisele et al. taught that chicken α7 nAChR / mouse 5-HT 3 R behaves quite differently from the native α7 nAChR in that the pore element does not conduct calcium, but is actually blocked by calcium ions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinuclidines-substituted-multi-cycli-heteroaryls for treatment of disease
  • Quinuclidines-substituted-multi-cycli-heteroaryls for treatment of disease
  • Quinuclidines-substituted-multi-cycli-heteroaryls for treatment of disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0235] Example 1: N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydrofuro[2,3-c]pyridine-5-carboxamide Dihydrochloride:

[0236]

[0237] Acid preparation:

[0238] 2-chloro-3-pyridinol (20.0g, 0.154mol), NaHCO 3 (19.5g, 0.232mol, 1.5equ) and 150ml of water were placed in the flask. Place the flask in an oil bath at 90°C, and after 5 minutes, add six different doses of 37% aqueous formaldehyde (40.5ml, 0.541mol, 3.5equ) in the following order: 12ml, 3×8ml and then 2.2ml, all A final 2.3 ml was added after 90 minute intervals followed by stirring at 90°C for 15 hours. The reaction was stirred at 90°C for an additional 4 hours, then the flask was cooled in an ice bath. The pH of the reaction was then adjusted to 1 with 6N HCl. The reaction was stirred in an ice bath for 1.5 hours, an unwanted solid formed. Unwanted solids were removed by filtration and the filtrate was extracted seven times with EtOAc. Combine the organic extracts, concentrate in vacuo, add toluene to the...

Embodiment 2

[0247] Example 2: N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-2-carboxamide:

[0248]

[0249] Acid preparation:

[0250] Add 4-hydroxypyridine (23.8g, 250mmol) and Na to 80ml of water 2 CO 3 (7.4 g, 70 mmol). The reaction mixture was heated to reflux, and 250 ml of an aqueous solution of iodine (23.2 g, 92 mmol) and potassium iodide (80 g, 482 mmol) was slowly added dropwise. After the addition, the reaction was refluxed for 1 hour. The mixture was filtered hot to remove by-products, the filtrate was cooled to room temperature, solids were removed and dried to give 3-iodo-4-pyridinol (C10) (32% yield). C 5 h 4 The HRMS (FAB) calculated value of INO+H is 221.9418, and the measured value is 221.9416 (M+H) + .

[0251] in N 2 To a suspension of triphenylphosphine (166mg, 0.63mmol) and palladium acetate (71mg, 0.32mmol) in 25ml DMF in a dry flask was added C10 (3.5g, 15.8mmol). Propionaldehyde diethyl acetal (2.3ml, 15.8mmol), cuprous iodide (120mg, 0.63m...

Embodiment 3

[0256] Example 3: N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-chlorofuro[2,3-c]pyridine-5-carboxamide hydrochloride :

[0257]

[0258] Method B:

[0259] Acid C7 (435mg, 2.2mmol) and TEA (307μl, 2.2mmol) in CH 2 Cl 2 (10ml) was stirred until dissolved, diphenylphosphoryl azide (431μl, 2.0mmol) was added, and the reaction was stirred at room temperature for 20 minutes. Add R-(+)-3-aminoquinucidine (252 mg, 2.0 mmol) in 2 Cl 2 (3 mL) solution and the reaction was stirred at room temperature for 18 hours. The solution was diluted with MeOH and loaded on an AG 50W-X2 resin column (hydrogen form). The column was flushed with MeOH and the product was eluted with 5% TEA / MeOH solution onto an AMBERJET 4400 OH resin column. The eluted product was concentrated to an oil. The crude product was purified by chromatography on 25 g of slurry packed silica gel with 0.3% ammonium hydroxide / 4% MeOH / CH 2 Cl 2 , then with 0.5% Ammonium Hydroxide / 5% MeOH / CH 2 Cl 2 , and finally with 0.5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides compounds of Formula (I).These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula (I) are useful to treat diseases or conditions in which alpha7 is known to be involved.

Description

field of invention [0001] Nicotinic acetylcholine receptors (nAChRs) play an important role in central nervous system (CNS) activity. Specifically, they are known to be involved in cognition, learning, mood, emotion and neuroprotection. There are several types of nicotinic acetylcholine receptors, each of which appears to play a different role in regulating CNS function. Nicotine affects all such receptors and has a variety of activities. Unfortunately, not all activities are desirable. In fact, one of the most undesirable properties of nicotine is its addiction and low efficacy-to-safety ratio. The present invention relates to molecules that have a greater effect on α7 nAChRs than other closely related members of this large family of ligand-gated receptors. Thus, the present invention provides compounds that are active drug molecules with fewer side effects. Background of the invention [0002] Cell surface receptors are generally excellent and effective drug targets. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/439A61P1/14A61P3/04A61P25/00C07D491/048A61P25/02A61P25/04A61P25/14A61P25/16A61P25/18A61P25/22A61P25/24A61P25/28A61P25/34A61P25/36A61P27/02A61P27/06A61P31/18A61P35/00A61P43/00C07D471/04C07D495/04C07D519/00
CPCC07D519/00A61P1/14A61P25/00A61P25/02A61P25/04A61P25/14A61P25/16A61P25/18A61P25/22A61P25/24A61P25/28A61P25/34A61P25/36A61P27/02A61P27/06A61P3/04A61P31/18A61P35/00A61P43/00C07D453/02
Inventor D·G·维施喀S·C·雷兹D·W·匹奥特罗斯克V·E·小格罗皮
Owner PHARMACIA & UPJOHN CO